3M has named Chris Barry executive vice president and group president of the Medical Solutions Division (MSD) of its Health Care Business Group. Barry will join 3M on March 1 to drive profitable growth for MSD, the world leader in advanced wound care, through active portfolio management, product and business model innovation, and growth initiatives. He was most recently Chief Executive Officer of NuVasive and a member of its Board of Directors.

“We are excited to have Chris join us as we advance the spin-off of our planned, independent healthcare company,” said Bryan Hanson, CEO of 3M’s Health Care Business Group. “Chris is an innovative global leader and we will benefit from his deep expertise in the healthcare and medical device industry.”

The spin-off of the independent health care company, to be named Solventum, is expected in the first half of 2024, subject to final approval by 3M's Board of Directors and other required conditions. Until the spin-off, the Health Care Business continues to be part of 3M and governed by the policies and procedures of 3M.

Prior to joining NuVasive, Barry served as Senior Vice President and President of Surgical Innovations at Medtronic, its second largest business unit with $5.5 billion in annual revenue. Before the acquisition of Covidien by Medtronic, Barry was President, Advanced Surgical Technologies of Covidien, where he led global strategy, product portfolio and U.S. commercial teams for the $3.2 billion global business unit. He spent more than 15 years in increasing commercial and executive leadership roles at Covidien. Chris is a member of the LivaNova Board of Directors.